Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 21 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

19%

4 trials in Phase 3/4

Results Transparency

50%

6 of 12 completed trials have results

Key Signals

5 recruiting6 with results

Enrollment Performance

Analytics

N/A
8(66.7%)
Phase 3
3(25.0%)
Phase 4
1(8.3%)
12Total
N/A(8)
Phase 3(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT07390409Not Yet Recruiting

ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.

Role: lead

NCT06408142Recruiting

Universal Test and Connect for HIV Service Delivery in South Africa

Role: collaborator

NCT05723484Completed

Comparing a Novel Point-of-care Cytokine Biomarker Lateral Flow Test With Nucleic Acid Amplification Tests for Detection of Sexually Transmitted Infections and Bacterial Vaginosis

Role: collaborator

NCT06662747Recruiting

Vaginal Microbiome Research Consortium for Africa

Role: collaborator

NCT05091580Not ApplicableSuspended

Effectiveness and Cost-Effectiveness of Depression Treatment for Individuals With TB in South Africa

Role: collaborator

NCT06423612Not ApplicableRecruiting

Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING PUMA)

Role: collaborator

NCT05040841Not ApplicableActive Not Recruiting

Supporting Sustained HIV Treatment Adherence After Initiation

Role: collaborator

NCT03231358Phase 3Completed

Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa

Role: collaborator

NCT04151602Completed

Transmission of Tuberculosis Among Illicit Drug Use Linkages

Role: collaborator

NCT06807736Recruiting

PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.

Role: lead

NCT05602376Not ApplicableRecruiting

Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging

Role: lead

NCT04937881Phase 3Completed

PK of TAF and TDF for PrEP in Pregnant and Postpartum Women

Role: collaborator

NCT05119348Not ApplicableCompleted

Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments

Role: lead

NCT04364165Not ApplicableCompleted

Effect of U=U Messaging on HIV in South Africa

Role: collaborator

NCT03826199Phase 4Completed

Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study)

Role: collaborator

NCT06133686Phase 3Not Yet Recruiting

Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa

Role: collaborator

NCT03923231Completed

Pharmacokinetics of Atazanavir in Special Populations

Role: collaborator

NCT04241809Completed

Bioaerosol Sampling in Suspected Pulmonary Tuberculosis

Role: lead

NCT04333498Not ApplicableCompleted

Use of Antiretroviral (ARV) Drug Levels in Dried Blood Spots (DBS) to Assess and Manage ART Adherence in South Africa

Role: collaborator

NCT04781400Not ApplicableCompleted

Bidirectional, Upbeat Communication and Differentiated, Distanced Care for Young People

Role: lead